Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity

Cancer Letters

Volumn 257, Issue 1, 2007, Pages 97-106

  Lu, Lei ^a   Yang, Zhonghan ^a   Zhu, Baohe ^b   Fang, Shuhuan ^a   Yang, Xia ^a   Cai, Weibin ^a   Li, Chaoyang ^c   Ma, Jian xing ^d   Gao, Guoquan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Hepatocellular carcinoma; HIF 1 ; KBP; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; KALLIKREIN BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEAR TRANSLOCATION; PARAMETER; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TUMOR CELL; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 34648825647     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.07.008     Document Type: Article

References (40)

1. Poon R.T., Fan S.T., Lo C.M., et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann. Surg. 229 (1999) 216-222
2. Miorentino M., Altimari A., Ravaioli M., et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin. Cancer Res. 10 (2004) 789-1795
3. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
4. Cao Y. Antiangiogenic cancer therapy. Semin. Cancer Biol. 14 (2004) 139-145
5. Yang X., Cheng R., Li C.Y., et al. Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity. Cancer Biol. Ther. 5 (2006) 399-405
6. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
7. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (2002) 15-18
8. Jimenez B., and Volpert O.V. Mechanistic insights on the inhibition of tumor angiogenesis. J. Mol. Med. 78 (2001) 663-672
9. Gao G.Q., Li Y., Zhang D.C., et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 489 (2001) 270-276
10. Gao G.Q., and Ma J.X. Tipping the balance for angiogenic disorders. Drug Discov. Today 7 3 (2002) 171-172
11. Jin J., Guan M., Sima J., et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor in pterygia. Cornea 22 5 (2003) 473-477
12. Gao G.Q., Li Y., Fant J., et al. Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in Brown Norway and Sprague-Dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 51 (2002) 1218-1225
13. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb. Symp. Quant. Biol. 5 9 (1994) 471-482
14. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
15. Bhoola K.D., Figueroa C.D., and Worthy K. Bioregulation of kinins: kallikrein, kininogens, and kininases. Pharmacol. Rev. 44 (1992) 1-80
16. Chao J., Miao R.Q., Chen V., et al. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol. Chem. 382 (2001) 15-21
17. Miao R.Q., Agata J., Chao L., et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 100 (2002) 3245-3252
18. Chai K.X., Ma J.X., Murray S.R., et al. Molecular cloning and analysis of the rat kallikrein-binding protein gene. J. Biol. Chem. 266 (1991) 16029-16036
19. Chao J., Chai K.X., Chen L.M., et al. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J. Biol. Chem. 265 (1990) 16394-16401
20. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., and Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285 (1999) 1926-1928
21. Zhang M., Volpert O., Shi Y.H., et al. Maspin is an angiogenesis inhibitor. Nat. Med. 6 (2000) 196-199
22. Gao G.Q., Shao C.K., Zhang S.X., et al. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 46 (2003) 689-698
23. Wang C.R., Chen S.Y., Wu C.L., et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 52 (2005) 1319-1324
24. Garcia M., Fernandez-Garcia N.I., Rivas V., et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res. 64 (2004) 5632-5642
25. Streck C.J., Zhang Y., Zhou J., et al. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J. Pediatr. Surg. 40 (2005) 236-243
26. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. USA 95 (1998) 6367-6372
27. Li H., Lu H., Griscelli F., Opolon P., Sun L.Q., Ragot T., et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 5 (1998) 1105-1113
28. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324 (1991) 1-8
29. Song Z.Y., Wen S.Q., Peng J.P., Huang X., and Qian K.D. Significance of vascular endothelial growth factor expression and its correlation with inducible nitric oxide synthase in gastric cancer. World J. Gastroenterol. 10 (2004) 1250-1255
30. Gastl G., Hermann T., Steurer M., et al. Angiogenesis as a target for tumor treatment. Oncology 54 (1997) 177-184
31. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today 6 (2001) 1005-1024
32. Cao Y.H. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33 (2001) 357-369
33. Chen L.M., Chao L., and Chao J. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci. 60 (1997) 1431-1435
34. Ma J.X., Chao L., Zhou G., and Chao J. Expression and characterization of rat kallikrein-binding protein in Escherichia coli. Biochem. J. 292 (1993) 825-832
35. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
36. Chen V.C., Chao L., Pimenta D.C., et al. Identification of a major heparin-binding site in kallistatin. J. Biol. Chem. 276 (2001) 1276-1284
37. Miao R.Q., Chen V., Chao L., and Chao J. Structural elements of kallistatin required for inhibition of angiogenesis. Am. J. Physiol. Cell Physiol. 284 (2003) C1604-C1613
38. Safran M., and Kaelin W.G.J. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111 (2003) 779-783
39. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9 (2003) 677-684
40. Mohamed K.M., Le A., Duong H., et al. Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. Exp. Mol. Pathol. 76 (2004) 143-152